Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
19
Active, not recruiting, industry sponsors, Kidney and urology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed344
19 trials
Showing 1 to 19, recently updated first.
- A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaPivotal-lookingActive, not recruiting
Kind Pharmaceuticals LLCIndustry
NCT07494409 · 300 participants (planned) · Start Oct 31, 2025 · Primary completion Feb 20, 2027
Drug: AND017 capsules; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Shanghai, China
- A Trial of HRS-5965 Capsule in Primary IgA NephropathyPivotal-lookingActive, not recruiting
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07014826 · 389 participants · Start Jun 4, 2025 · Primary completion Oct 2027
Drug: HRS-5965; Placebo · For: Primary IgA Nephropathy
Sites: Beijing, China
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Pivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06531824 · 8,371 participants · Start Aug 30, 2024 · Primary completion Dec 31, 2026
Drug: BI 690517; Placebo matching BI 690517 and 1 more · For: Kidney Disease, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Beverly Hills, California · 562 sites in all
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)Pivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07107945 · 135 participants · Start Dec 9, 2025 · Primary completion Apr 16, 2027
Drug: Empagliflozin; Placebo · For: Chronic Kidney Disease
Sites: Birmingham, Alabama; Palo Alto, California; Sacramento, California · 93 sites in all
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05797610 · 459 participants · Start Aug 8, 2023 · Primary completion May 25, 2028
Drug: Sefaxersen (RO7434656); Placebo · For: Primary IgA Nephropathy
Sites: Birmingham, Alabama; Glendale, California; Los Angeles, California · 162 sites in all
- A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaPivotal-lookingActive, not recruiting
BayerBayer (BAYRY)
NCT05196035 · 219 participants (planned) · Start Mar 28, 2022 · Primary completion Apr 10, 2027
Drug: Finerenone (Kerendia, BAY94-8862); Placebo · For: Chronic Kidney Disease; Proteinuria
Sites: Palo Alto, California; San Diego, California; Hollywood, Florida · 132 sites in all
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06087835 · 1,835 participants · Start Nov 7, 2023 · Primary completion Feb 18, 2027
Drug: Zibotentan/Dapagliflozin; Dapagliflozin · For: Chronic Kidney Disease With High Proteinuria
Sites: Huntsville, Alabama; Sun City West, Arizona; Bakersfield, California · 296 sites in all
- A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseasePivotal-lookingActive, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05970172 · 98 participants · Start Jan 16, 2024 · Primary completion Oct 30, 2027
Drug: Roxadustat · For: Chronic Kidney Disease; Renal Anemia
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 47 sites in all
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06383390 · 10,000 participants (planned) · Start Apr 30, 2024 · Primary completion Feb 2029
Drug: Retatrutide; Placebo · For: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)
Sites: Alabaster, Alabama; Birmingham, Alabama; Daphne, Alabama · 742 sites in all
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06291376 · 584 participants · Start Mar 29, 2024 · Primary completion Jan 5, 2026
Drug: Ravulizumab; Placebo · For: Immunoglobulin A Nephropathy; IgAN
Sites: Alabaster, Alabama; Phoenix, Arizona; Los Angeles, California · 246 sites in all
- Atacicept in Subjects With IgA NephropathyPivotal-lookingActive, not recruiting
Vera Therapeutics, Inc.Industry
NCT04716231 · 428 participants · Start Jun 29, 2023 · Primary completion May 15, 2025
Drug: Atacicept · For: IgA Nephropathy; Berger Disease
Sites: Brisbane, California
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisPivotal-lookingActive, not recruiting
BiocadIndustry
NCT07119372 · 228 participants (planned) · Start Mar 1, 2025 · Primary completion May 12, 2026
Drug: BCD-131 (pegdarbepoetin beta); Mircera (methoxypolyethylene glycol-epoetin beta) · For: Anemia; Chronic Kidney Disease; Chronic Kidney Disease Patients on Hemodialysis and 1 more
Sites: Krasnodar, Russia; Novosibirsk, Russia; Orenburg, Russia · 14 sites in all
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePivotal-lookingActive, not recruiting
ProkidneyIndustry
NCT05099770 · 685 participants (planned) · Start Jan 5, 2022 · Primary completion Dec 2029
Drug: Renal Autologous Cell Therapy (REACT/ rilparencel) · For: Type 2 Diabetes Mellitus; Chronic Kidney Diseases
Sites: Huntsville, Alabama; Tucson, Arizona; Beverly Hills, California · 88 sites in all
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)Pivotal-lookingActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05248646 · 530 participants · Start Mar 15, 2022 · Primary completion May 13, 2026
Drug: Sibeprenlimab 400 mg; Placebo · For: Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 308 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06268873 · 2,554 participants · Start Mar 29, 2024 · Primary completion Feb 24, 2028
Drug: Baxdrostat/dapagliflozin; Dapagliflozin in combination with placebo · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Phoenix, Arizona; Surprise, Arizona · 565 sites in all
- Atrasentan in Patients With IgA NephropathyPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04573478 · 404 participants · Start Dec 11, 2020 · Primary completion Apr 14, 2028
Drug: Atrasentan; Placebo and 1 more · For: IgA Nephropathy; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Alhambra, California; Glendale, California · 135 sites in all
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingActive, not recruiting
Alpine Immune Sciences Inc, A Subsidiary of VertexIndustry
NCT06564142 · 605 participants · Start Aug 30, 2024 · Primary completion Jan 30, 2028
Drug: Povetacicept; Placebo (matched to Povetacicept) · For: Immunoglobulin A Nephropathy
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 318 sites in all
- A Study of Zigakibart in Adults With IgA NephropathyPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05852938 · 383 participants · Start Jul 6, 2023 · Primary completion Aug 10, 2027
Drug: BION-1301; Placebo · For: IgA Nephropathy; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Huntsville, Alabama; San Francisco, California · 200 sites in all
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)Pivotal-lookingActive, not recruiting
RemeGen Co., Ltd.Industry
NCT05799287 · 318 participants · Start Apr 28, 2023 · Primary completion Jun 2026
Drug: Telitacicept; Placebo · For: Primary IgA Nephropathy
Sites: Bengbu, China; Hefei, China; Wuhu, China · 101 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.